Robert Bristow

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6488764/publications.pdf

Version: 2024-02-01

250 papers	18,945 citations	9775 73 h-index	14736 127 g-index
265 all docs	265 docs citations	265 times ranked	23548 citing authors

#	Article	IF	Citations
1	Subpathologies and genomic classifier for treatment individualization of post-prostatectomy radiotherapy. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 5.e1-5.e13.	0.8	2
2	Prostate zones and cancer: lost in transition?. Nature Reviews Urology, 2022, 19, 101-115.	1.9	25
3	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 6-11.	0.9	4
4	Redox-responsive nanoparticles enhance radiation therapy by altering multifaceted radio-resistance mechanisms in human castration-resistant prostate cancer cells and xenografts. Radiotherapy and Oncology, 2022, 170, 213-223.	0.3	8
5	Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study. European Urology, 2022, 82, 201-211.	0.9	2
6	Prostate cancer. Nature Reviews Disease Primers, 2021, 7, 9.	18.1	434
7	Lost in application: Measuring hypoxia for radiotherapy optimisation. European Journal of Cancer, 2021, 148, 260-276.	1.3	21
8	Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer. BMC Urology, 2021, 21, 96.	0.6	5
9	Prostate cancer. Lancet, The, 2021, 398, 1075-1090.	6.3	240
10	Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors. Cancer Research, 2021, 81, 5833-5848.	0.4	7
11	Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse. Nature Communications, 2021, 12, 6248.	5.8	15
12	Dimensional reduction based on peak fitting of Raman micro spectroscopy data improves detection of prostate cancer in tissue specimens. Journal of Biomedical Optics, 2021, 26, .	1.4	4
13	The telomere length landscape of prostate cancer. Nature Communications, 2021, 12, 6893.	5.8	7
14	Temporal Stability and Prognostic Biomarker Potential of the Prostate Cancer Urine miRNA Transcriptome. Journal of the National Cancer Institute, 2020, 112, 247-255.	3.0	33
15	The tip of the iceberg: predicting PARP inhibitor efficacy in prostate cancer. Lancet Oncology, The, 2020, 21, 17-19.	5.1	8
16	Impact of Lineage Plasticity to and from a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers. Molecular Cell, 2020, 80, 562-577.	4.5	54
17	Determining the Impact of Spatial Heterogeneity on Genomic Prognostic Biomarkers for Localized Prostate Cancer. European Urology Oncology, 2020, , .	2.6	13
18	Sex differences in oncogenic mutational processes. Nature Communications, 2020, 11, 4330.	5.8	60

#	Article	IF	Citations
19	Clinical and functional characterization of CXCR1/CXCR2 biology in the relapse and radiotherapy resistance of primary PTEN-deficient prostate carcinoma. NAR Cancer, 2020, 2, zcaa012.	1.6	8
20	Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy caseâ€"control study with multicohort validation. PLoS Medicine, 2020, 17, e1003281.	3.9	19
21	Bad neighbours: hypoxia and genomic instability in prostate cancer. British Journal of Radiology, 2020, 93, 20200087.	1.0	23
22	[¹⁸F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial. BMJ Open, 2020, 10, e035959.	0.8	8
23	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European Urology, 2020, 77, 508-547.	0.9	278
24	Divergent mutational processes distinguish hypoxic and normoxic tumours. Nature Communications, 2020, 11, 737.	5.8	90
25	Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer. Nature Communications, 2020, 11, 441.	5.8	51
26	The European Organisation for Research and Treatment of Cancer, State of Science in radiation oncology and priorities for clinical trials meeting report. European Journal of Cancer, 2020, 131, 76-88.	1.3	15
27	Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors. Cancer Cell, 2019, 36, 674-689.e6.	7.7	52
28	Genome-wide germline correlates of the epigenetic landscape of prostate cancer. Nature Medicine, 2019, 25, 1615-1626.	15.2	45
29	ONECUT2 is a driver of neuroendocrine prostate cancer. Nature Communications, 2019, 10, 278.	5.8	143
30	Oxygen-enhanced MRI Is Feasible, Repeatable, and Detects Radiotherapy-induced Change in Hypoxia in Xenograft Models and in Patients with Nonâ€"small Cell Lung Cancer. Clinical Cancer Research, 2019, 25, 3818-3829.	3.2	51
31	The Proteogenomic Landscape of Curable Prostate Cancer. Cancer Cell, 2019, 35, 414-427.e6.	7.7	168
32	A Phase 1 Pilot Study of Preoperative Radiation Therapy for Prostate Cancer: Long-Term Toxicity and Oncologic Outcomes. International Journal of Radiation Oncology Biology Physics, 2019, 104, 61-66.	0.4	8
33	Widespread and Functional RNA Circularization in Localized Prostate Cancer. Cell, 2019, 176, 831-843.e22.	13.5	317
34	The influence of BRCA2 mutation on localized prostate cancer. Nature Reviews Urology, 2019, 16, 281-290.	1.9	53
35	Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 103, 84-91.	0.4	36
36	TP53 and Prognosis in mCRPC Survival: Biology or Coincidence?. Clinical Cancer Research, 2019, 25, 1699-1701.	3.2	4

#	Article	IF	Citations
37	Molecular landmarks of tumor hypoxia across cancer types. Nature Genetics, 2019, 51, 308-318.	9.4	480
38	Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2019, 17, 38-45.	0.9	29
39	Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. Lancet Oncology, The, 2018, 19, e240-e251.	5.1	108
40	Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nature Genetics, 2018, 50, 682-692.	9.4	182
41	The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression. Cell, 2018, 173, 1003-1013.e15.	13.5	176
42	Curative Radiation Therapy at Time of Progression Under Active Surveillance Compared With Up-front Radical Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 100, 702-709.	0.4	1
43	A Partner in Crime: Tumor-associated Stroma and Metastatic Prostate Cancer. European Urology, 2018, 73, 533-534.	0.9	1
44	NanoStringNormCNV: pre-processing of NanoString CNV data. Bioinformatics, 2018, 34, 1034-1036.	1.8	2
45	The Future of Radiobiology. Journal of the National Cancer Institute, 2018, 110, 329-340.	3.0	76
46	Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer. EBioMedicine, 2018, 31, 182-189.	2.7	132
47	Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories. Cancer Cell, 2018, 34, 996-1011.e8.	7.7	190
48	The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation. BMC Urology, 2018, 18, 78.	0.6	14
49	Hedgehog inhibition mediates radiation sensitivity in mouse xenograft models of human esophageal adenocarcinoma. PLoS ONE, 2018, 13, e0194809.	1.1	16
50	Valection: design optimization for validation and verification studies. BMC Bioinformatics, 2018, 19, 339.	1.2	2
51	Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017. Clinical Cancer Research, 2018, 24, 3500-3509.	3.2	3
52	Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations. BMC Cancer, 2018, 18, 8.	1.1	93
53	Genomic hallmarks of localized, non-indolent prostate cancer. Nature, 2017, 541, 359-364.	13.7	462
54	Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. Nature Communications, 2017, 8, 13671.	5.8	182

#	Article	IF	Citations
55	Significant Radiation Enhancement Effects by Gold Nanoparticles in Combination with Cisplatin in Triple Negative Breast Cancer Cells and Tumor Xenografts. Radiation Research, 2017, 187, 147-160.	0.7	44
56	Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary Cancers. Oncologist, 2017, 22, 152-157.	1.9	9
57	The Evolving Narrative of DNA Repair Gene Defects: Distinguishing Indolent from Lethal Prostate Cancer. European Urology, 2017, 71, 748-749.	0.9	9
58	Intraductal Carcinoma of the Prostate: Anonymous to Ominous. European Urology, 2017, 72, 496-498.	0.9	14
59	Human tissue Kallikreins: Blood levels and response to radiotherapy in intermediate risk prostate cancer. Radiotherapy and Oncology, 2017, 124, 427-432.	0.3	10
60	Improved outcomes with dose escalation in localized prostate cancer treated with precision image-guided radiotherapy. Radiotherapy and Oncology, 2017, 123, 459-465.	0.3	18
61	A Prostate Cancer â€œ Nimbosus â€• Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. European Urology, 2017, 72, 665-674.	0.9	142
62	Targeting DNA repair for precision radiotherapy: Balancing the therapeutic ratio. Current Problems in Cancer, 2017, 41, 265-272.	1.0	16
63	Comparison of pre-processing methods for Infinium HumanMethylation450 BeadChip array. Bioinformatics, 2017, 33, 3151-3157.	1.8	9
64	Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer. Journal of the National Cancer Institute, 2017, 109, .	3.0	13
65	Mitochondrial mutations drive prostate cancer aggression. Nature Communications, 2017, 8, 656.	5.8	100
66	Loss of p27kip1 increases genomic instability and induces radio-resistance in luminal breast cancer cells. Scientific Reports, 2017, 7, 595.	1.6	22
67	TMPRSS2â€"ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer. Nature Genetics, 2017, 49, 1336-1345.	9.4	161
68	Radiosensitization by gold nanoparticles: Will they ever make it to the clinic?. Radiotherapy and Oncology, 2017, 124, 344-356.	0.3	122
69	The effect of bowel preparation regime on interfraction rectal filling variation during image guided radiotherapy for prostate cancer. Radiation Oncology, 2017, 12, 50.	1.2	7
70	Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. European Urology, 2017, 72, 22-31.	0.9	37
71	Long-term outcomes of a phase II trial of moderate hypofractionated image-guided intensity modulated radiotherapy (IG-IMRT) for localized prostate cancer. Radiotherapy and Oncology, 2017, 122, 93-98.	0.3	23
72	Response. Journal of the National Cancer Institute, 2017, 109, .	3.0	0

#	Article	IF	Citations
73	Long non-coding RNA urothelial carcinoma associated 1 (UCA1) mediates radiation response in prostate cancer. Oncotarget, 2017, 8, 4668-4689.	0.8	74
74	Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. Journal of Clinical Oncology, 2017, 35, 2299-2305.	0.8	241
75	The Clinical Genomics of Prostate Cancer. , 2017, , 97-110.		2
76	Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model. Oncotarget, 2017, 8, 87638-87646.	0.8	10
77	Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer. Frontiers in Oncology, 2016, 6, 24.	1.3	20
78	MATE2 Expression Is Associated with Cancer Cell Response to Metformin. PLoS ONE, 2016, 11, e0165214.	1.1	25
79	Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts. PLoS ONE, 2016, 11, e0167272.	1.1	18
80	Clonality of localized and metastatic prostate cancer. Current Opinion in Urology, 2016, 26, 219-224.	0.9	9
81	Testosterone in Androgen Receptor Signaling and DNA Repair: Enemy or Frenemy?. Clinical Cancer Research, 2016, 22, 3124-3126.	3.2	15
82	Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer. Nature Genetics, 2016, 48, 1142-1150.	9.4	196
83	Dual Action Enhancement of Gold Nanoparticle Radiosensitization by Pentamidine in Triple Negative Breast Cancer. Radiation Research, 2016, 185, 549.	0.7	29
84	BAMQL: a query language for extracting reads from BAM files. BMC Bioinformatics, 2016, 17, 305.	1.2	20
85	PMH 9907: Longâ€term outcomes of a randomized phase 3 study of shortâ€term bicalutamide hormone therapy and doseâ€escalated externalâ€beam radiation therapy for localized prostate cancer. Cancer, 2016, 122, 2595-2603.	2.0	14
86	Nanoparticle-Enabled Selective Destruction of Prostate Tumor Using MRI-Guided Focal Photothermal Therapy. Prostate, 2016, 76, 1169-1181.	1.2	28
87	Liver Failure After Abdominal Irradiation: Identifying the Right Suspects. Journal of Clinical Oncology, 2016, 34, e80-e83.	0.8	1
88	In Vitro and In Vivo Studies of a New Class of Anticancer Molecules for Targeted Radiotherapy of Cancer. Molecular Cancer Therapeutics, 2016, 15, 640-650.	1.9	12
89	A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: a retrospective cohort study. Oncotarget, 2016, 7, 57726-57736.	0.8	55
90	The initiation of a multidisciplinary bladder cancer clinic and the uptake of neoadjuvant chemotherapy: A time-series analysis. Canadian Urological Association Journal, 2016, 10, 25.	0.3	17

#	Article	IF	Citations
91	Not all gleason pattern 4 prostate cancers are created equal: A study of latent prostatic carcinomas in a cystoprostatectomy and autopsy series. Prostate, 2015, 75, 1277-1284.	1.2	47
92	Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nature Genetics, 2015, 47, 736-745.	9.4	395
93	MR-guided Prostate Biopsy for Planning of Focal Salvage after Radiation Therapy. Radiology, 2015, 274, 181-191.	3.6	40
94	Targeting Tumour Hypoxia with PARP Inhibitors: Contextual Synthetic Lethality. Cancer Drug Discovery and Development, 2015, , 345-361.	0.2	0
95	Hypoxia and Predicting Radiation Response. Seminars in Radiation Oncology, 2015, 25, 260-272.	1.0	73
96	Cyclic hypoxia does not alter RAD51 expression or PARP inhibitor cell kill in tumor cells. Radiotherapy and Oncology, 2015, 116, 388-391.	0.3	8
97	Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nature Genetics, 2015, 47, 367-372.	9.4	380
98	Synergistic action of image-guided radiotherapy and androgen deprivation therapy. Nature Reviews Urology, 2015, 12, 193-204.	1.9	41
99	Phase 2 trial of guideline-based postoperative image guided intensity modulated radiation therapy for prostate cancer: Toxicity, biochemical, and patient-reported health-related quality-of-life outcomes. Practical Radiation Oncology, 2015, 5, e473-e482.	1.1	24
100	In vivo studies of the PARP inhibitor, AZD-2281, in combination with fractionated radiotherapy: An exploration of the therapeutic ratio. Radiotherapy and Oncology, 2015, 116, 486-494.	0.3	48
101	Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 85-94.	0.8	107
102	Appropriateness of Using Patient-Derived Xenograft Models for Pharmacologic Evaluation of Novel Therapies for Esophageal/Gastro-Esophageal Junction Cancers. PLoS ONE, 2015, 10, e0121872.	1.1	21
103	Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression. Oncotarget, 2015, 6, 1900-1919.	0.8	80
104	Use of Sequenom Sample ID PlusÂ® SNP Genotyping in Identification of FFPE Tumor Samples. PLoS ONE, 2014, 9, e88163.	1.1	17
105	Prostate cancer screening characteristics in men with BRCA1/2 mutations attending a high-risk prevention clinic. Canadian Urological Association Journal, 2014, 8, 783.	0.3	7
106	Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncology, The, 2014, 15, 1521-1532.	5.1	291
107	Hypoxia and Cellular Localization Influence the Radiosensitizing Effect of Gold Nanoparticles (AuNPs) in Breast Cancer Cells. Radiation Research, 2014, 182, 475-488.	0.7	62
108	High tumor interstitial fluid pressure identifies cervical cancer patients with improved survival from radiotherapy plus cisplatin versus radiotherapy alone. International Journal of Cancer, 2014, 135, 1692-1699.	2.3	29

#	Article	IF	Citations
109	WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. Acta Neuropathologica Communications, 2014, 2, 174.	2.4	37
110	Hypoxia Provokes Base Excision Repair Changes and a Repair-Deficient, Mutator Phenotype in Colorectal Cancer Cells. Molecular Cancer Research, 2014, 12, 1407-1415.	1.5	47
111	In Regard to Freedland et al. International Journal of Radiation Oncology Biology Physics, 2014, 88, 237-240.	0.4	4
112	Prostate Cancer Genomics as a Driver of Personalized Medicine. , 2014, , 233-245.		1
113	Current Status and Recommendations for the Future ofÂResearch, Teaching, and Testing in the Biological Sciences of Radiation Oncology: Report of the American Society for Radiation Oncology Cancer Biology/Radiation Biology Task Force, Executive Summary. International Journal of Radiation Oncology Biology Physics, 2014, 88, 11-17.	0.4	26
114	DNA Double-Strand Break Repair Pathway Choice Is Directed by Distinct MRE11 Nuclease Activities. Molecular Cell, 2014, 53, 7-18.	4.5	466
115	SeqControl: process control for DNA sequencing. Nature Methods, 2014, 11, 1071-1075.	9.0	10
116	Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2014, 74, 195-204.	1.1	23
117	ShatterProof: operational detection and quantification of chromothripsis. BMC Bioinformatics, 2014, 15, 78.	1.2	49
118	Synergistic Nanoparticulate Drug Combination Overcomes Multidrug Resistance, Increases Efficacy, and Reduces Cardiotoxicity in a Nonimmunocompromised Breast Tumor Model. Molecular Pharmaceutics, 2014, 11, 2659-2674.	2.3	54
119	Deriving patient-specific planning target volume for partial bladder image guided radiation therapy. Practical Radiation Oncology, 2014, 4, 323-329.	1.1	7
120	Linking the History of Radiation Biology to the Hallmarks of Cancer. Radiation Research, 2014, 181, 561-577.	0.7	37
121	Intratumoral Hypoxia as the Genesis of Genetic Instability and Clinical Prognosis in Prostate Cancer. Advances in Experimental Medicine and Biology, 2014, 772, 189-204.	0.8	28
122	RNF8-Independent Lys63 Poly-Ubiquitylation Prevents Genomic Instability in Response to Replication-Associated DNA Damage. PLoS ONE, 2014, 9, e89997.	1.1	1
123	NBNgain is predictive for adverse outcome following image-guided radiotherapy for localized prostate cancer. Oncotarget, 2014, 5, 11081-11090.	0.8	30
124	In Reply to Nieder. International Journal of Radiation Oncology Biology Physics, 2013, 85, 581.	0.4	0
125	Imatinib Radiosensitizes Bladder Cancer by Targeting Homologous Recombination. Cancer Research, 2013, 73, 1611-1620.	0.4	30
126	Inherently Multimodal Nanoparticle-Driven Tracking and Real-Time Delineation of Orthotopic Prostate Tumors and Micrometastases. ACS Nano, 2013, 7, 4221-4232.	7.3	101

#	Article	IF	Citations
127	Neoplastic cell response to tiopronin-coated gold nanoparticles. Nanomedicine: Nanotechnology, Biology, and Medicine, 2013, 9, 264-273.	1.7	14
128	Investigations of antioxidant-mediated protection and mitigation of radiation-induced DNA damage and lipid peroxidation in murine skin. International Journal of Radiation Biology, 2013, 89, 618-627.	1.0	26
129	4FISH-IF, a Four-Color Dual-Gene FISH Combined with p63 Immunofluorescence to Evaluate NKX3.1 and MYC Status in Prostate Cancer. Journal of Histochemistry and Cytochemistry, 2013, 61, 500-509.	1.3	5
130	miRNA-95 Mediates Radioresistance in Tumors by Targeting the Sphingolipid Phosphatase SGPP1. Cancer Research, 2013, 73, 6972-6986.	0.4	127
131	Primary esophageal and gastro-esophageal junction cancer xenograft models: clinicopathological features and engraftment. Laboratory Investigation, 2013, 93, 397-407.	1.7	24
132	Inhibition of breast cancer local relapse by targeting p70S6 kinase activity. Journal of Molecular Cell Biology, 2013, 5, 428-431.	1.5	19
133	Reprogramming Metabolism with Metformin Improves Tumor Oxygenation and Radiotherapy Response. Clinical Cancer Research, 2013, 19, 6741-6750.	3.2	268
134	TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair. Clinical Cancer Research, 2013, 19, 5202-5209.	3.2	39
135	Changes in apparent diffusion coefficient and T₂ relaxation during radiotherapy for prostate cancer. Journal of Magnetic Resonance Imaging, 2013, 37, 909-916.	1.9	74
136	Tumor hypoxia as a driving force in genetic instability. Genome Integrity, 2013, 4, 5.	1.0	181
137	Resistance to Bleomycin in Cancer Cell Lines Is Characterized by Prolonged Doubling Time, Reduced DNA Damage and Evasion of G2/M Arrest and Apoptosis. PLoS ONE, 2013, 8, e82363.	1.1	23
138	The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers. Canadian Urological Association Journal, 2013, 5, 31.	0.3	0
139	Electron transfer-based combination therapy of cisplatin with tetramethyl- p -phenylenediamine for ovarian, cervical, and lung cancers. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 10175-10180.	3.3	31
140	PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy. Clinical Cancer Research, 2012, 18, 1015-1027.	3.2	119
141	Tumor Hypoxia Predicts Biochemical Failure following Radiotherapy for Clinically Localized Prostate Cancer. Clinical Cancer Research, 2012, 18, 2108-2114.	3.2	233
142	NKX3.1 Haploinsufficiency Is Prognostic for Prostate Cancer Relapse following Surgery or Image-Guided Radiotherapy. Clinical Cancer Research, 2012, 18, 308-316.	3.2	43
143	Chronic hypoxia compromises repair of DNA double-strand breaks to drive genetic instability. Journal of Cell Science, 2012, 125, 189-199.	1.2	108
144	Association Between Germline HOXB13 G84E Mutation and Risk of Prostate Cancer. Journal of the National Cancer Institute, 2012, 104, 1260-1262.	3.0	62

#	Article	IF	Citations
145	Discordance between phosphorylation and recruitment of 53BP1 in response to DNA double-strand breaks. Cell Cycle, 2012, 11, 1432-1444.	1.3	43
146	Pathological Predictors for Site of Local Recurrence After Radiotherapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 82, e441-e448.	0.4	52
147	Inverse Relationship Between Biochemical Outcome and Acute Toxicity After Image-Guided Radiotherapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, 608-616.	0.4	10
148			

#	Article	IF	Citations
163	Hypoxia disrupts the Fanconi anemia pathway and sensitizes cells to chemotherapy through regulation of UBE2T. Radiotherapy and Oncology, 2011, 101, 190-197.	0.3	36
164	The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination. Radiotherapy and Oncology, 2011, 101, 59-65.	0.3	31
165	Role of Principal Component Analysis in Predicting Toxicity in Prostate Cancer Patients Treated With Hypofractionated Intensity-Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2011, 81, e415-e421.	0.4	25
166	Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways. Radiation Oncology, 2011, 6, 144.	1.2	73
167	Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer. Nature Reviews Clinical Oncology, 2011, 8, 107-113.	12.5	28
168	In Situ DNA Repair Assays As Guides to Personalized Breast Cancer Chemotherapeutics: Ready for Prime Time?. Journal of Clinical Oncology, 2011, 29, 2130-2132.	0.8	2
169	MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks. Cell Cycle, 2011, 10, 2218-2232.	1.3	111
170	The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers. Canadian Urological Association Journal, 2011, 5, e31-e35.	0.3	13
171	Poly(ADP-Ribose) Polymerase Inhibition as a Model for Synthetic Lethality in Developing Radiation Oncology Targets. Seminars in Radiation Oncology, 2010, 20, 274-281.	1.0	123
172	Introduction: DNA Repair and Radiotherapy Targeting: An Overview. Seminars in Radiation Oncology, 2010, 20, 215-216.	1.0	1
173	DNA Repair Targeting and Radiotherapy: A Focus on the Therapeutic Ratio. Seminars in Radiation Oncology, 2010, 20, 217-222.	1.0	68
174	A Cinematic Magnetic Resonance Imaging Study of Milk of Magnesia Laxative and an Antiflatulent Diet to Reduce Intrafraction Prostate Motion. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1072-1078.	0.4	52
175	Response to â€œIntraoperative Radiotherapy During Radical Prostatectomy for Locally Advanced Prostate Cancer: Technical and Dosimetric Aspectsâ€•(Int J Radiat Oncol Biol PhysÂ2009; in press). International Journal of Radiation Oncology Biology Physics, 2010, 76, 1277.	0.4	1
176	Ionizing Radiation Activates AMP-Activated Kinase (AMPK): A Target for Radiosensitization of Human Cancer Cells. International Journal of Radiation Oncology Biology Physics, 2010, 78, 221-229.	0.4	177
177	Tumor Cell Kill by c-MYC Depletion: Role of MYC-Regulated Genes that Control DNA Double-Strand Break Repair. Cancer Research, 2010, 70, 8748-8759.	0.4	84
178	Rnf8 deficiency impairs class switch recombination, spermatogenesis, and genomic integrity and predisposes for cancer. Journal of Experimental Medicine, 2010, 207, 983-997.	4.2	112
179	MRE11 Expression Is Predictive of Cause-Specific Survival following Radical Radiotherapy for Muscle-Invasive Bladder Cancer. Cancer Research, 2010, 70, 7017-7026.	0.4	184
180	Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment. Cancer Research, 2010, 70, 8045-8054.	0.4	211

#	Article	IF	Citations
181	â€œContextualâ€•Synthetic Lethality and/or Loss of Heterozygosity: Tumor Hypoxia and Modification of DNA Repair. Clinical Cancer Research, 2010, 16, 4553-4560.	3.2	100
182	Gold Nanoparticles as Radiation Sensitizers in Cancer Therapy. Radiation Research, 2010, 173, 719.	0.7	547
183	Late Residual Î³-H2AX Foci In Murine Skin are Dose Responsive and Predict RadiosensitivityIn Vivo. Radiation Research, 2010, 173, 1-9.	0.7	59
184	The MMS22L-TONSL Complex Mediates Recovery from Replication Stress and Homologous Recombination. Molecular Cell, 2010, 40, 619-631.	4.5	106
185	Tumor senescence and radioresistant tumor-initiating cells (TICs): let sleeping dogs lie!. Breast Cancer Research, 2010, 12, 111.	2.2	9
186	Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer. Acta OncolÃ³gica, 2010, 49, 888-894.	0.8	32
187	Rnf8 deficiency impairs class switch recombination, spermatogenesis, and genomic integrity and predisposes for cancer. Journal of Cell Biology, 2010, 189, i6-i6.	2.3	0
188	Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. Molecular Cancer Therapeutics, 2009, 8, 203-213.	1.9	95
189	Longitudinal Cytokine Expression during IMRT for Prostate Cancer and Acute Treatment Toxicity. Clinical Cancer Research, 2009, 15, 5576-5583.	3.2	53
190	Imaging radiation biology for optimised radiation therapy. International Journal of Radiation Biology, 2009, 85, 729-731.	1.0	1
191	Highâ€resolution array CGH identifies novel regions of genomic alteration in intermediateâ€risk prostate cancer. Prostate, 2009, 69, 1091-1100.	1.2	75
192	Image guided dose escalated prostate radiotherapy: still room to improve. Radiation Oncology, 2009, 4, 50.	1.2	57
193	Comparing oxygen-sensitive MRI (BOLD R2*) with oxygen electrode measurements: A pilot study in men with prostate cancer. International Journal of Radiation Biology, 2009, 85, 805-813.	1.0	101
194	Germline MutY Human Homologue Mutations and Colorectal Cancer: A Multisite Case-Control Study. Gastroenterology, 2009, 136, 1251-1260.	0.6	197
195	Microscopic imaging of DNA repair foci in irradiated normal tissues. International Journal of Radiation Biology, 2009, 85, 732-746.	1.0	51
196	IMRT and molecular biological approaches in radiotherapy for prostate cancer. European Journal of Cancer, 2009, 45, 429-430.	1.3	1
197	Tumor Hypoxia as a Modifier of DNA Strand Break and Cross-Link Repair. Current Molecular Medicine, 2009, 9, 401-410.	0.6	34
198	Preface. Cancer and Metastasis Reviews, 2008, 27, 337-338.	2.7	2

#	Article	IF	Citations
199	Biomarkers for DNA DSB inhibitors and radiotherapy clinical trials. Cancer and Metastasis Reviews, 2008, 27, 445-458.	2.7	36
200	Practical approaches to proteomic biomarkers within prostate cancer radiotherapy trials. Cancer and Metastasis Reviews, 2008, 27, 375-385.	2.7	12
201	Analysis of variants in DNA damage signalling genes in bladder cancer. BMC Medical Genetics, 2008, 9, 69.	2.1	38
202	Hypoxia, DNA repair and genetic instability. Nature Reviews Cancer, 2008, 8, 180-192.	12.8	991
203	Characterization of Mutant MUTYH Proteins Associated With Familial Colorectal Cancer. Gastroenterology, 2008, 135, 499-507.e1.	0.6	89
204	PRIMA-1met radiosensitizes prostate cancer cells independent of their MTp53-status. Radiotherapy and Oncology, 2008, 86, 407-411.	0.3	36
205	A randomized comparison of interfraction and intrafraction prostate motion with and without abdominal compression. Radiotherapy and Oncology, 2008, 88, 88-94.	0.3	25
206	A phase I trial of pre-operative radiotherapy for prostate cancer: Clinical and translational studies. Radiotherapy and Oncology, 2008, 88, 53-60.	0.3	30
207	A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiotherapy and Oncology, 2008, 88, 258-268.	0.3	130
208	Chronic Hypoxia Decreases Synthesis of Homologous Recombination Proteins to Offset Chemoresistance and Radioresistance. Cancer Research, 2008, 68, 605-614.	0.4	286
209	Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Molecular Cancer Therapeutics, 2008, 7, 993-999.	1.9	66
210	WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells. Molecular Cancer Therapeutics, 2008, 7, 980-992.	1.9	15
211	Biology of Cancer. , 2008, , 3-22.		1
212	Radiation Effects and Radioprotection in MC3T3-E1 Mouse Calvarial Osteoblastic Cells. Plastic and Reconstructive Surgery, 2008, 122, 1025-1035.	0.7	16
213	Overview of Cancer Molecular Radiobiology. Cancer Treatment and Research, 2008, , 115-131.	0.2	2
214	Novel Chemical Enhancers of Heat Shock Increase Thermal Radiosensitization through a Mitotic Catastrophe Pathway. Cancer Research, 2007, 67, 695-701.	0.4	37
215	Androgen Withdrawal in Patients Reduces Prostate Cancer Hypoxia: Implications for Disease Progression and Radiation Response. Cancer Research, 2007, 67, 6022-6025.	0.4	109
216	Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 303-309.	0.8	98

#	Article	IF	Citations
217	Homologous recombination and prostate cancer: A model for novel DNA repair targets and therapies. Radiotherapy and Oncology, 2007, 83, 220-230.	0.3	67
218	Tumor hypoxia, DNA repair and prostate cancer progression: new targets and new therapies. Future Oncology, 2007, 3, 329-341.	1.1	75
219	Phase II Trial of Hypofractionated Image-Guided Intensity-Modulated Radiotherapy for Localized Prostate Adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1084-1089.	0.4	139
220	Treatment of radiation proctitis with hyperbaric oxygen. Radiotherapy and Oncology, 2006, 78, 91-94.	0.3	57
221	A Randomized Phase III Study of Neoadjuvant Hormonal Therapy in Patients with Localized Prostate Cancer. Clinical Genitourinary Cancer, 2006, 5, 235-237.	0.9	2
222	Radiation and New Molecular Agents Part I: Targeting ATM-ATR Checkpoints, DNA Repair, and the Proteasome. Seminars in Radiation Oncology, 2006, 16, 51-58.	1.0	97
223	Promyelocytic leukemia nuclear bodies behave as DNA damage sensors whose response to DNA double-strand breaks is regulated by NBS1 and the kinases ATM, Chk2, and ATR. Journal of Cell Biology, 2006, 175, 55-66.	2.3	166
224	Low and intermediate risk prostate cancer-- role of hormonal therapy with external beam radiation therapy. Canadian Journal of Urology, 2006, 13 Suppl 2, 63-7.	0.0	1
225	Alterations in DNA Repair Gene Expression under Hypoxia: Elucidating the Mechanisms of Hypoxia-Induced Genetic Instability. Annals of the New York Academy of Sciences, 2005, 1059, 184-195.	1.8	69
226	Detection of genetic instability at HER-2/neu and p53 loci in breast cancer cells sing Cometâ€"FISH. Breast Cancer Research and Treatment, 2005, 91, 89-94.	1.1	33
227	Male BRCA1 and BRCA2 mutation carriers: a pilot study investigating medical characteristics of patients participating in a prostate cancer prevention clinic. Prostate, 2005, 65, 124-129.	1.2	22
228	Hypoxia-Induced Down-regulation of BRCA1 Expression by E2Fs. Cancer Research, 2005, 65, 11597-11604.	0.4	313
229	Evidence for the Direct Binding of Phosphorylated p53 to Sites of DNA Breaks In vivo. Cancer Research, 2005, 65, 10810-10821.	0.4	98
230	Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy. Cancer, 2005, 104, 891-905.	2.0	51
231	Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiotherapy and Oncology, 2005, 76, 168-176.	0.3	172
232	Basis of Cell Kill Following Clinical Radiotherapy. , 2005, , 293-320.		10
233	Defective DNA Strand Break Repair after DNA Damage in Prostate Cancer Cells. Cancer Research, 2004, 64, 8526-8533.	0.4	108
234	The p53 protein family and radiation sensitivity: Yes or no?. Cancer and Metastasis Reviews, 2004, 23, 237-257.	2.7	116

#	Article	IF	Citations
235	Down-Regulation of Rad51 and Decreased Homologous Recombination in Hypoxic Cancer Cells. Molecular and Cellular Biology, 2004, 24, 8504-8518.	1.1	341
236	A randomized trial of supine vs. prone positioning in patients undergoing escalated dose conformal radiotherapy for prostate cancer. Radiotherapy and Oncology, 2004, 70, 37-44.	0.3	98
237	Recommendations for the future of translational radiobiology research: a Canadian perspective. Radiotherapy and Oncology, 2004, 70, 159-164.	0.3	12
238	Re: Vikram, B., The PSA conundrum. Radiother Oncol, 2004. 71(1): p. 1â€"2. Radiotherapy and Oncology, 2004, 73, 252-254.	0.3	1
239	Resistance to DNA-damaging agents is discordant from experimental metastatic capacity in MEF ras-transformants-expressing gain of function MTp53. Oncogene, 2003, 22, 2960-2966.	2.6	22
240	Recurrent prostate cancer following external beam radiotherapy. Urologic Clinics of North America, 2003, 30, 751-763.	0.8	27
241	Education and Training for Radiation Scientists: Radiation Research Program and American Society of Therapeutic Radiology and Oncology Workshop, Bethesda, Maryland, May 12â€"14, 2003. Radiation Research, 2003, 160, 729-737.	0.7	31
242	Combined-Modality Treatment of Solid Tumors Using Radiotherapy and Molecular Targeted Agents. Journal of Clinical Oncology, 2003, 21, 2760-2776.	0.8	131
243	Comment on "Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis" (II). Science, 2003, 302, 1894d-1894.	6.0	37
244	Chk2 Is a Tumor Suppressor That Regulates Apoptosis in both an Ataxia Telangiectasia Mutated (ATM)-Dependent and an ATM-Independent Manner. Molecular and Cellular Biology, 2002, 22, 6521-6532.	1.1	354
245	Expression of Different Mutant p53 Transgenes in Neuroblastoma Cells Leads to Different Cellular Responses to Genotoxic Agents. Experimental Cell Research, 2002, 275, 122-131.	1.2	18
246	Radioresistant MTp53-expressing rat embryo cell transformants exhibit increased DNA-dsb rejoining during exposure to ionizing radiation. Oncogene, 1998, 16, 1789-1802.	2.6	38
247	T1/T2 Glottic Cancer Managed by External Beam Radiotherapy: The Influence of Pretreatment Hemoglobin on Local Control. International Journal of Radiation Oncology Biology Physics, 1998, 41, 347-353.	0.4	169
248	The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. Radiotherapy and Oncology, 1996, 40, 197-223.	0.3	185
249	P53-mediated radioresistance does not correlate with metastatic potential in tumorigenic rat embryo cell lines following oncogene transfection. International Journal of Radiation Oncology Biology Physics, 1996, 34, 341-355.	0.4	11
250	p53 Protein expression or protein function? Re: Awwad et al. IJROBP 34(2):323â€"332; 1996. International Journal of Radiation Oncology Biology Physics, 1996, 35, 1123-1124.	0.4	2